AI-ACLD Study: Artificial Intelligence in Advanced Chronic Liver Disease (AI-ACLD)

July 21, 2026 updated by: Antonio Galante

Application of Artificial Intelligence Using Wearable Technology in Patients With Advanced Chronic Liver Disease (ACLD): a Trajectomics Approach.

The research project studies the possibility of using an artificial intelligence-based system in patients with advanced chronic liver disease (liver cirrhosis) to record variations in a patient's health status, with the aim of early identification of clinical improvement or deterioration. The system is based on the collection and processing of various clinical parameters through an Apple Watch. The study aims to evaluate whether the data generated by this system correlate with patients' clinical evolution and whether its use may ultimately contribute to improved care management and quality of life.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

8

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Switzerland
      • Lugano, Switzerland, 6900
        • Ente Ospedaliero Cantonale

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients hospitalized at Ente Ospedaliero Cantonale (EOC) in Lugano or Bellinzona or patients followed at the Department for Gastroenterology and Hepatology, Ente Ospedaliero Cantonale will be assessed for inclusion in the study

Description

Inclusion Criteria:

  • Adults aged 18-75 years
  • Diagnosis of advanced chronic liver disease (ACLD).
  • Either:
  • hospitalized for hepatic decompensation or acute-on-chronic liver failure (ACLF), including ascites, hepatorenal syndrome, hepatic encephalopathy, bacterial infection, gastrointestinal bleeding, or jaundice; or
  • outpatient with Child-Pugh B cirrhosis and no evidence of hepatic decompensation or ACLF at enrolment.
  • Willing and able to provide written informed consent.

Exclusion Criteria:

  • Inability or refusal to provide written informed consent
  • Inability to wear or correctly use the Apple Watch
  • Patients with hepatocellular carcinoma beyond the Milan Criteria (one lesion up to 5 cm or 3 lesions up to 3 cm in diameter)
  • Presence of hepatic decompensation or ACLF

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility and accuracy of machine learning analysis of individual health data collected by wearable device.
Time Frame: From enrollment to the end of the study (6 months)

The primary outcome is to assess the feasibility and accuracy of machine learning analysis of individual health data collected by wearable device and to describe their patterns during hospitalization due to symptoms of decompensation or ACLF and in outpatients until hospitalization due to decompensation or ACLF in patients with liver cirrhosis. Health data continuously collected through a dedicated wearable device application comprise: heart rate and heart rate variability (HR; HRV), oxygen saturation (SpO₂), ECG (QRS, PQ, PT Tpe interval), sleep quality and duration, daily step count, tremor intensity (Hz), typing speed (taps/time).

The single unit of measure used to assess the feasibility of the wearable device is the usable data acquisition rate (%), defined as the percentage of monitoring data successfully collected and suitable for analysis.
From enrollment to the end of the study (6 months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Antonio Galante

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 29, 2022

Primary Completion (Actual)

January 17, 2024

Study Completion (Actual)

January 17, 2024

Study Registration Dates

First Submitted

July 16, 2026

First Submitted That Met QC Criteria

July 21, 2026

First Posted (Actual)

July 23, 2026

Study Record Updates

Last Update Posted (Actual)

July 23, 2026

Last Update Submitted That Met QC Criteria

July 21, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • AI-ACLD Study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Advance Chronic Liver Disease (ACLD)

Clinical Trials on Apple Watch

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe